Relevant bibliographies by topics / Immunotherapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Immunotherapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 5 October 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immunotherapy"

1

Bakulesh, Khamar. "Immunotherapy of Bladder Cancer." Cancer Medicine Journal 3, no. 2 (December 31, 2020): 49–62. http://dx.doi.org/10.46619/cmj.2020.3-1020.

Full text
Abstract:
Bladder cancer used to be the only cancer treated by immunotherapy in form of intravesical BCG. Since approval of BCG for Non muscle invasive bladder cancer (NMIBC), there has been significant advancement in our knowledge about immune alteration in cancer and availability of immunotherapeutic agents. Tumor induced cell mediated immunosuppression is identified as a key factor for development and progression of cancer. Immune suppression in bladder cancer is predominantly through Macrophages. Myeloid derived suppressor cell, NK cells, Treg and expression of immune checkpoint receptor inhibitors also contribute to immune suppression. BCG induces innate immune response and its efficacy is limited to NMIBC. Novel immunotherapeutic agents evaluated in bladder cancer are administered locally or systemically to induce innate or adaptive immune response. Systemic administration of antibodies against PD-1/PD-L1 axis are now approved for treatment of locally advanced/metastatic bladder cancer as a first line as well as second line therapy. Pembrolizumab is also approved for BCG unresponsive NMIBC. Since response to immunotherapy are neither uniform nor universal, attempts are made to identify prognostic and predictive biomarkers. Identified biomarkers lack desired specificity and sensitivity. Several immune approaches using innate as well as adaptive mechanism are under evaluation to improve outcome of intravesical BCG or immune check point receptor inhibitors.
APA, Harvard, Vancouver, ISO, and other styles
2

Kim, Edwin H., and Arvil Wesley Burks. "Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy." Allergy 75, no. 6 (February 28, 2020): 1337–46. http://dx.doi.org/10.1111/all.14220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fay, Emily K., and Julie N. Graff. "Immunotherapy in Prostate Cancer." Cancers 12, no. 7 (July 1, 2020): 1752. http://dx.doi.org/10.3390/cancers12071752.

Full text
Abstract:
Immunotherapy encompasses a wide range of therapies to engage the immune system to target malignancies. In recent years, immunotherapy has made a major impact on treatment of metastatic cancer and has altered standard of care for many tumor types. However, predicting and understanding responses across tumor types has been challenging. While some metastatic cancers have shown dramatic responses to immunotherapy, such as melanoma, lung cancer, and renal cell carcinoma, prostate cancer has generally failed to show a significant response. However, small series of prostate cancer patients have shown impressive responses to cellular and immunotherapy. This review summarizes the current data for immunotherapy’s use in prostate cancer, as well as how currently available data might help predict patient responses to immunotherapy. Specifically, we will review vaccine-based therapies, immune checkpoint inhibitors, and future directions that are actively being explored.
APA, Harvard, Vancouver, ISO, and other styles
4

Bintintan, Vasile, Claudia Burz, Irena Pintea, Adriana Muntean, Diana Deleanu, Iulia Lupan, and Gabriel Samasca. "Predictive Factors of Immunotherapy in Gastric Cancer: A 2024 Update." Diagnostics 14, no. 12 (June 13, 2024): 1247. http://dx.doi.org/10.3390/diagnostics14121247.

Full text
Abstract:
Many studies on gastric cancer treatment have identified predictors of immunotherapy benefits. This article provides an update on the major developments in research related to predictive factors of immunotherapy for gastric cancer. We used the search term “predictive factors, immunotherapy, gastric cancer” to find the most current publications in the PubMed database related to predictive factors of immunotherapy in gastric cancer. Programmed cell death, genetic, and immunological factors are the main study topics of immunotherapy’s predictive factors in gastric cancer. Other preventive factors for immunotherapy in gastric cancer were also found, including clinical factors, tumor microenvironment factors, imaging factors, and extracellular factors. Since there is currently no effective treatment for gastric cancer, we strongly propose that these studies be prioritized.
APA, Harvard, Vancouver, ISO, and other styles
5

Nelson, Harold S., Melina Makatsori, and Moises A. Calderon. "Subcutaneous Immunotherapy and Sublingual Immunotherapy." Immunology and Allergy Clinics of North America 36, no. 1 (February 2016): 13–24. http://dx.doi.org/10.1016/j.iac.2015.08.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sveikata, Lukas, Andreas Charidimou, and Anand Viswanathan. "Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab." Stroke 53, no. 1 (January 2022): 298–302. http://dx.doi.org/10.1161/strokeaha.121.036873.

Full text
Abstract:
We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-β immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy’s efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.
APA, Harvard, Vancouver, ISO, and other styles
7

S V S, Gulakavarapu, Narapaneni Sravanthi, Praneeth Ulavala, and S. Chandrababu. "Immunotherapy and the Management of Allergies: An Overview of Monoclonal Antibody Therapy and Allergen Immunotherapy." International Journal of Science and Research (IJSR) 12, no. 9 (September 5, 2023): 1051–53. http://dx.doi.org/10.21275/mr23911124247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shi, Junhan. "Applications of immune checkpoint inhibitors (ICIs) in the medical fields." Highlights in Science, Engineering and Technology 36 (March 21, 2023): 321–30. http://dx.doi.org/10.54097/hset.v36i.5698.

Full text
Abstract:
ICIs are a kind of immunotherapy that works by preventing immune checkpoints from functioning normally, which are essential immune system components. ICIs are currently the most used immunotherapy regimen. Based on the patient's health, the cancer type, the length of the illness, and the dose of inhibitors the patient can tolerate, the therapy can cause side effects of indeterminate duration and varying degrees. However, the therapy remains beneficial for patients. Therefore, the effects of immunotherapy on the human body are still an issue that needs to be explored. An overview of ICIs in immunotherapy will be given in this paper, including the following concepts: (i) General information on treatments with immune checkpoint inhibitors (ii)The immunotherapy’s mechanism and application (iii) Problems and complications with ICI therapies (iv) Ways that the immunotherapy can be improved and the future direction of ICI.
APA, Harvard, Vancouver, ISO, and other styles
9

Gillespy, Kristen, Margie D. Dixon, and Rebecca D. Pentz. "Communication about immunotherapy: Barriers and information to discuss." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 6543. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.6543.

Full text
Abstract:
6543 Background: Since immunotherapy is a promising new therapeutic approach to cancer treatment, improving physician/patient communication about this approach is important. No communication guidelines exist. To begin to fill this gap, we identified provider and patient preferences for information, and identified barriers to communication about immunotherapy. Methods: We qualitatively interviewed 15 oncology professionals who offer immunotherapy treatment about the information they deemed important to communicate to patients and the communication barriers. After a discussion about immunotherapy options with a provider, we interviewed 18 oncology patients about the information that was most useful to them and their impressions of immunotherapy. We captured impressions on two 1-5 scales with 5 being ‘very positive impression’ and ‘very likely to be cured’ and by picking words from a list of positive and negative terms like ‘effective’ and ‘risky.’ All open-ended questions were qualitatively coded. We reached saturation of themes with 18 patients. Results: Patients identified 4 useful topics to discuss: treatment options, benefits, treatment logistics, and side effects. Providers identified 3 topics important topics to convey: side effects, realistic view of benefit and treatment logistics. The most frequently provider-identified barrier to communication was patients’ baseline misconceptions about immunotherapy’s effectiveness. Supporting this, patients’ impressions were very positive (average of 4 on impressions scale and 3.9 on potential to be cured scale.) The most frequently chosen word patients chose to describe immunotherapy treatment was ‘hopeful’ (10/18 55%). Conclusions: There is largely agreement on the important topics to discuss about immunotherapy, though half of the patients thought a discussion of treatment options would be useful and only one physicians mentioned options. Of note, communication is hampered by patients’ preconceptions about immunotherapy’s effectiveness. Communication guidelines should identify techniques to effectively overcome this barrier.
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 548 (April 1995): 8. http://dx.doi.org/10.2165/00128415-199505480-00029.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immunotherapy"

1

Dadi, C. N. "Cancer immunotherapy." Thesis, Sumy State University, 2015. http://essuir.sumdu.edu.ua/handle/123456789/40532.

Full text
Abstract:
Over the years we have resorted to radiation, chemotherapy and surgery in fighting cancer. Unlike the latter mentioned forms of therapy cancer immunotherapy is one of the more recent approaches. Cancer immunotherapy focuses on enhancing the body‘s immune system in fighting cancer.
APA, Harvard, Vancouver, ISO, and other styles
2

Ferrell, Melissa Leann. "Sublingual Immunotherapy." Diss., The University of Arizona, 2015. http://hdl.handle.net/10150/565918.

Full text
Abstract:
One of the most common reasons people seek primary care and emergency care is to reduce the symptoms of allergies, such as hay fever. To meet this high demand, several recent FDA-approved methods for treating seasonal and perennial allergies have been developed, including sublingual immunotherapy tablets. Furthermore, no longer must a patient endure allergy shots; this can now be delivered sublingually. Although this method has been shown to have high safety and efficacy, very few clinicians actually utilize this form of therapy. The purpose of this paper is describe the use of sublingual immunotherapy among Nurse Practitioners (NPs) and discuss barriers that may prevent its use. Nurse Practitioners working in primary care settings were surveyed regarding their use of sublingual immunotherapy. Although many nurse practitioners treat patients with allergic disease, not one participant reported using sublingual immunotherapy. This discussion outlines some of the reasons NPs are not currently utilizing this method of allergy treatment and the findings are compared with the extant literature. This paper culminates in an evidence-based algorithm to outline best practices for utilizing sublingual immunotherapy to reduce allergy symptoms.
APA, Harvard, Vancouver, ISO, and other styles
3

Walker, Samantha Mary. "Immunotherapy for summer hayfever." Thesis, Imperial College London, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.248036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Michael, Agnieszka. "Genetic immunotherapy for cancer." Thesis, St George's, University of London, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.437318.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Kwan, Byron H. (Byron Hua). "Integrin-targeted cancer immunotherapy." Thesis, Massachusetts Institute of Technology, 2016. http://hdl.handle.net/1721.1/104220.

Full text
Abstract:
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2016.
Cataloged from PDF version of thesis.
Includes bibliographical references.
Integrins are a family of heterodimeric cell surface receptors that are functionally important for cell adhesion, migration and proliferation. Certain integrins, especially those that are known to recognize the arginine-glycine-aspartate (RGD) motif, are heavily overexpressed in many cancers relative to healthy tissue, making them attractive targets for therapeutic intervention. However, prior attempts to antagonize these integrins as a cancer therapy have all failed in the clinic. In this thesis, we instead exploit integrins as a target tumor antigen in the context of immunotherapy. The engineered cysteine knot peptide, 2.5F, is highly crossreactive and capable of recognizing multiple RGD-binding integrins. Our initial attempts to utilize this binder as a targeting moiety for delivering IL-2 as an immunocytokine failed. Mathematical modeling results indicated that immunocytokines, unless adhering to specific design criteria, are unlikely to benefit from targeting and may actually exhibit limited efficacy. Therefore, we "deconstructed" this immunocytokine into its functional parts: extended half-life IL-2 and 2.5F-Fc, the antibody-like construct directed against RGD-binding integrins. This combination immunotherapeutic approach was able to synergistically control tumor growth in three syngeneic murine models of cancer, including durable cures and development of immunological memory. Contrary to prior attempts at integrin-targeting, the mechanism of action was independent of functional integrin antagonism, including effects on angiogenesis and tumor proliferation. In fact, efficacy of this therapy depended solely upon the adaptive and innate arms of immunity, specifically CD8+ T cells, macrophages, and dendritic cells. Furthermore, checkpoint blockade, the gold standard for immunotherapy to date, can further enhance the efficacy of this therapeutic approach. This signifies that the combination of IL-2 and 2.5F-Fc exerts a distinct, yet complementary immune response that opens the door for clinical translation.
by Byron H. Kwan.
Ph. D.
APA, Harvard, Vancouver, ISO, and other styles
6

Harrison, Simon James. "Immunotherapy in multiple myeloma." Thesis, University of Glasgow, 2005. http://theses.gla.ac.uk/1054/.

Full text
Abstract:
The BDCA antibodies allowed reliable measurement of dendritic cell (DC) subsets and B cell numbers in the blood of normal subjects, and patients with MM throughout the disease course. The numbers of blood myeloid DC (BmDC) and blood plasmacytoid DC (BpDC) are low throughout the course of the disease, and only improve for a short period of time following autologous HSCT. Thalidomide therapy of patients with relapsed disease was associated with an increase in BmDC1 and BpDC numbers. Monocytes, mobilised at the time of stem cell collection, were used to produce mature DC (matDC) from MM patients and normal donors (ND). The matDC produced from MM patients were of poorer quality as compared to those from ND, despite using combinations of GM/IL-4, GM/IL-13, X4 and MIMIC in the production process. The combinations that contained the X4 maturation cocktail produced the best quality matDC. The DC/T cell system is abnormal in MM patients. Despite this, it is possible to produce antigen loaded mature MoDC from MM patients. When combined with T cell pre-stimulation and IL-2 expansion, these DC are capable of inducing anti-MM cytotoxic T cells, which exhibit considerable anti-MM cytolytic activity. However, the DC from MM patients still display abnormal chemokine receptor expression, which may inhibit their capability to migrate to lymph nodes in-vivo in order to generate these cytotoxic T cell responses. These observations will aid in the optimisation of DC based immune therapies for MM, and suggest that a combined immunotherapy approach using pre-stimulated T cells, MM Ag primed DC and IL-2 may produce better clinical responses in MM patients.
APA, Harvard, Vancouver, ISO, and other styles
7

Jain, Renu Zaghouani Habib. "Immunotherapy for autoimmune diabetes." Diss., Columbia, Mo. : University of Missouri-Columbia, 2008. http://hdl.handle.net/10355/6869.

Full text
Abstract:
The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Title from PDF of title page (University of Missouri--Columbia, viewed on April 1, 2010). Vita. Thesis advisor: Habib Zaghouani. "May 2008" Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
8

Champiat, Stéphane. "Caractérisation clinique et biologique de l’hyperprogression tumorale lors du blocage de la voie PD-1/PD-L1." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS040.

Full text
Abstract:
Les anticorps bloquant les points de contrôle immunitaires modifient profondément la gestion des patients atteints de cancer. À la pointe de cette nouvelle classe d'agents anticancéreux, les anticorps anti-PD-1 / PD-L1 peuvent ainsi restaurer une réponse efficace des cellules T antitumorales. En conséquence, ces agents sont maintenant approuvés dans divers types de tumeurs, tels que le mélanome, le cancer bronchique non à petites cellules, le cancer du rein, les tumeurs ORL ou le cancer de la vessie. Ces nouvelles immunothérapies entraînent également de nouveaux profils de réponse tumorale tels que des réponses tumorales retardées ou des pseudoprogressions. Au fil de l’expérience acquise avec ces traitements, il a été observé chez certains patients un état de progression rapide de la maladie, ce qui pourrait suggérer que le blocage de points de contrôle immunitaire pourrait avoir un effet délétère en accélérant la maladie chez un sous-groupe de patients. Ce travail de thèse a permis de caractériser sur le plan clinique et biologique ce phénomène d’accélération de la croissance tumorale sous immunothérapie anti-checkpoint que nous avons définit “maladie hyperprogressive” (HPD). L’analyse transcriptomique d’échantillons tumoraux de ces patients a permis d’orienter vers un rôle spécifique de l’environnement myeloide
Immune checkpoint blocking antibodies are profoundly changing the management of patients with cancer. At the forefront of this novel anticancer agent class, anti-PD-1/PD-L1 antibodies can exhibit a significant activity by restoring an efficient antitumor T-cell response. As a result, these agents are now approved in various tumor types such as melanoma, squamous, and nonsquamous non–small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC) or bladder cancer. Interestingly, these new immunotherapies also result in novel tumor response patterns such as delayed tumor responses or pseudoprogressions. As experience grows with these therapeutics, anecdotal reports are relating rapid disease progressions, which could suggest that immune checkpoint blockade may have a deleterious effect by accelerating the disease in a subset of patients. This thesis work has made it possible to characterize clinically and biologically this phenomenon of accelerated tumor growth under anti-checkpoint immunotherapy, which we have defined as “hyperprogressive disease” (HPD). Transcriptomic analysis of tumour samples from these patients suggested a specific role for the myeloid environment
APA, Harvard, Vancouver, ISO, and other styles
9

Bracher, Marguerite. "IgE in immunotherapy of cancer." Thesis, King's College London (University of London), 2006. https://kclpure.kcl.ac.uk/portal/en/theses/ige-in-immunotherapy-of-cancer(08abceea-54a8-436c-9504-24742d57538d).html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Graff, Christilyn Paula. "Antibody engineering for tumor immunotherapy." Thesis, Massachusetts Institute of Technology, 2002. http://hdl.handle.net/1721.1/29279.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2002.
Vita.
Includes bibliographical references (leaves 130-140).
Antibodies have been used as cancer therapeutics for several decades. One area in which this therapy may be improved is the retention time of antibody in the tumor relative to normal tissue. In this Thesis, we have attempted to elucidate the mechanisms that are most influential to improving antibodies as cancer therapeutics. Carcinoembryonic antigen (CEA) has long been identified as a tumor-associated antigen. CEA is also quite stable, with a cell-surface shedding half-life of approximately 7 days. Directed evolution methodology has been utilized to design an antibody fragment with properties that would improve tumor retention. Specifically, antibody engineering methods were used to produce a humanized, extremely high affinity and stable single chain antibody fragment (scFv) against CEA. Several mutant scFv libraries were constructed and screened against soluble CEA with yeast surface display and fluorescent activated cell sorting (FACS). A series of antibodies were engineered that span three orders of magnitude in off-rate improvement. These antibody fragments show excellent stability at physiologically relevant temperatures. In addition, soluble protein expression levels were greatly improved. The final product has a dissociation half-life of approximately 7 days, currently the longest engineered half-life of an scFv against a tumor-associated antigen. Binding and diffusion in micrometastases was also modeled to gain an improved understanding of the quantitative interplay among the rate processes of diffusion, binding, degradation, and plasma clearance in tumor microspheroids.
(cont.) Modeling studies illuminated the importance of targeting stable tumor-associated antigens. The elimination rate of the antigen was of critical importance to the change in the therapeutic effect of antibodies with increasing affinity. The significance of this result in the context of previous experimental studies will be discussed. By affinity maturing an antibody with a dissociation half-life equal to the turnover half-life of the antigen, we have engineered an antibody with effectively irreversible binding to CEA. Differences in retention for the series of scFvs will thus be dominated by the off-rate of the antibody and not the half-life of CEA. With this in mind, the molecules designed in this study can be used to reconcile the issue of affinity's impact on efficacy in tumor therapy.
by Christilyn Paula Graff.
Ph.D.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Immunotherapy"

1

Naing, Aung, and Joud Hajjar, eds. Immunotherapy. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-79308-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Naing, Aung, and Joud Hajjar, eds. Immunotherapy. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-53156-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Naing, Aung, and Joud Hajjar, eds. Immunotherapy. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02505-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Naing, Aung, and Joud Hajjar, eds. Immunotherapy. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-41008-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

P, Allison James, and Dranoff Glenn, eds. Cancer immunotherapy. Amsterdam: Elsevier Academic Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ludewig, Burkhard, and Matthias W. Hoffmann. Adoptive Immunotherapy. New Jersey: Humana Press, 2004. http://dx.doi.org/10.1385/1592598625.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Curiel, Tyler J., ed. Cancer Immunotherapy. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-4732-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

F, Lockey Richard, and Bukantz Samuel C, eds. Allergen immunotherapy. New York: M. Dekker, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Siciliano, Velia, and Francesca Ceroni, eds. Cancer Immunotherapy. New York, NY: Springer US, 2024. http://dx.doi.org/10.1007/978-1-0716-3593-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Liau, Linda M., Donald P. Becker, Timothy F. Cloughesy, and Darell D. Bigner. Brain Tumor Immunotherapy. New Jersey: Humana Press, 2000. http://dx.doi.org/10.1385/1592590357.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Immunotherapy"

1

Volc, Sebastian, Kamran Ghoreschi, and Hui Shen. "Immunotherapy." In Practical Immunodermatology, 367–81. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-024-0902-4_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

del Bufalo, Francesca, and Franco Locatelli. "Immunotherapy." In Neuroblastoma, 237–69. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-18396-7_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Malmgren, Richard A. "Immunotherapy." In Cancer Management in Man, 270–80. Dordrecht: Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-2536-6_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Carroll, Marilyn E., Peter A. Santi, Joseph Zohar, Thomas R. E. Barnes, Peter Verheart, Per Svenningsson, Per E. Andrén, et al. "Immunotherapy." In Encyclopedia of Psychopharmacology, 618. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_3314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Seifert, Steven A., and Brandon J. Warrick. "Immunotherapy." In Critical Care Toxicology, 1–15. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-20790-2_176-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dorval, Th. "Immunotherapy." In Bone Metastases, 43–48. London: Springer London, 2002. http://dx.doi.org/10.1007/978-1-4471-3251-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dabski, Krzysztof, and Frederick Helm. "Immunotherapy." In Skin Cancer, 363–77. New York, NY: Springer New York, 1988. http://dx.doi.org/10.1007/978-1-4612-3790-7_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jasmin, Claude, T. A. Plunkett, and D. W. Miles. "Immunotherapy." In Textbook of Bone Metastases, 313–22. Chichester, UK: John Wiley & Sons, Ltd, 2006. http://dx.doi.org/10.1002/0470011610.ch24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nahler, Gerhard. "immunotherapy." In Dictionary of Pharmaceutical Medicine, 89. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_671.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tur, Mehmet Kemal, and Stefan Barth. "Immunotherapy." In Encyclopedia of Cancer, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_3014-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immunotherapy"

1

Fu, D., and Z. Chen. "Plasma Immunotherapy for Biomedical Applications." In 2024 IEEE International Conference on Plasma Science (ICOPS), 1. IEEE, 2024. http://dx.doi.org/10.1109/icops58192.2024.10627467.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mazur, Martyna, Maria Baczewska, Paulina Laskowska, Michał Gontarz, and Michał Ziemczonok. "Integrating Digital Holographic Microscopy with Data Analysis for Monitoring Lymphocyte Activation in Cellular Immunotherapy." In Digital Holography and Three-Dimensional Imaging, W4A.21. Washington, D.C.: Optica Publishing Group, 2024. http://dx.doi.org/10.1364/dh.2024.w4a.21.

Full text
Abstract:
The approach utilizing digital holographic microscopy (DHM) for analysing the status of T cells activation, the important part of CAR T cells immunotherapy, is presented. The preliminary research reveals usability of DHM in this field.
APA, Harvard, Vancouver, ISO, and other styles
3

"Tumor Immunotherapy." In International Conference on Medicine, Public Health and Biological Sciences. CASRP Publishing Company, Ltd. Uk, 2016. http://dx.doi.org/10.18869/mphbs.2016.139.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Naylor, Mark F., Kaili Liu, Ashley R. Hoover, and Wei R. Chen. "Biophotonics-based immunotherapy and checkpoint-based immunotherapy for cancer." In Biophotonics and Immune Responses XVI, edited by Wei R. Chen. SPIE, 2021. http://dx.doi.org/10.1117/12.2585180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shah, D. J., and C. M. Lo Cascio. "Immunotherapy Induced Pneumonitis." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Le, Anh Trang Nguyen, and Larysa Baraban. "Nanoelectronics for immunotherapy." In 2023 IEEE Nanotechnology Materials and Devices Conference (NMDC). IEEE, 2023. http://dx.doi.org/10.1109/nmdc57951.2023.10344017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gupta, A., G. Singh, and H. Jain. "Immunotherapy Induced Encephalitis." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5698.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Roth, L. "Novel agents beyond Immunotherapy." In ISCAYAHL 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1701868.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lozzo, Eneida Da, Edvaldo da Silva Trindade, Carolina De Oliveira, and Dorly de Buchi. "Homeopathic Immunotherapy against Cancer." In HRI London 2019—Cutting Edge Research in Homeopathy: Presentation Abstracts. The Faculty of Homeopathy, 2020. http://dx.doi.org/10.1055/s-0040-1702103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wang, Zihan. "Overview of Cancer Immunotherapy." In ICBBE '20: 2020 7th International Conference on Biomedical and Bioinformatics Engineering. New York, NY, USA: ACM, 2020. http://dx.doi.org/10.1145/3444884.3444919.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Immunotherapy"

1

Chen, Ru, Yao Sun, and Guoqi Sima. Comparative efficacy and tolerance of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis: a network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0078.

Full text
Abstract:
Review question / Objective: What is the effect of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis. Condition being studied: Immunotherapy is the classic treatment for allergic rhinitis. Intralymphatic immunotherapy is a new type of treatment. Currently, no studies have compared subcutaneous, sublingual and intralymphatic sublingual immunotherapy. At present, there is no review to compare the efficacy of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis.
APA, Harvard, Vancouver, ISO, and other styles
2

Suleyman, Narin, Robert Hughes, Jeremy Teoh, Anand Sharma, and Nikhil Vasdev. Immunotherapy in urological malignancy. BJUI Knowledge, September 2021. http://dx.doi.org/10.18591/bjuik.0735.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jadhav, Avadhoot. Towards a Universal Immunotherapy. New Science, September 2022. http://dx.doi.org/10.56416/591plq.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lubaroff, David M. Vaccine Immunotherapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2008. http://dx.doi.org/10.21236/ada484307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lee, Peter P. Integrated Immunotherapy for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2014. http://dx.doi.org/10.21236/ada613328.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lubaroff, David M. Vaccine Immunotherapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2010. http://dx.doi.org/10.21236/ada535354.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lubaroff, David M. Vaccine Immunotherapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2009. http://dx.doi.org/10.21236/ada509761.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rupprecht, Ruth M. Immunotherapy of Congenital SIV Infection. Fort Belvoir, VA: Defense Technical Information Center, October 1998. http://dx.doi.org/10.21236/ada358457.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lee, Peter P. Integrated Immunotherapy for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2013. http://dx.doi.org/10.21236/ada591526.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lubaroff, David. Vaccine Immunotherapy for Prostate Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2006. http://dx.doi.org/10.21236/ada462829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immunotherapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography